Skip to content
The Biotech Codex

The Biotech Codex

Decoding the Science of Life

  • Genetics
  • Biotechnology
  • Healthcare
  • AI
  • Lifestyle
  • Pharma
  • Biohacking
  • Nutrition
  • Testing
  • Opinion

Recent News

View All

FDA Expands Sevabertinib’s Accelerated Approval in HER2-Mutant NSCLC. The Response Data Are Encouraging, but Confirmation Still Matters

Jane Aubrey September 11, 2026September 11, 2026

BridgeBio’s PROPEL 3 Update Broadens the Infigratinib Story Beyond Height. The New Results Remain Exploratory.

Jane Aubrey September 10, 2026September 10, 2026

Leyden Labs’ RIG-101 Clears an Early Safety and Biomarker Hurdle. Phase 2 Must Now Show Clinical Protection.

Jane Aubrey September 9, 2026September 9, 2026

Rentosertib’s Aging-Clock Study Is a Biomarker Signal, Not Evidence That a Drug Reverses Human Aging

Jane Aubrey September 8, 2026September 8, 2026

Clover’s Phase 2 Combination-Vaccine Data Are Encouraging. They Are Not Yet an Efficacy Verdict.

Jane Aubrey September 7, 2026September 7, 2026

Banner Slider

Biotechnology

FDA Expands Sevabertinib’s Accelerated Approval in HER2-Mutant NSCLC. The Response Data Are Encouraging, but Confirmation Still Matters

The FDA has expanded the accelerated approval of sevabertinib, marketed as Hyrnuo, for adults with…

Jane Aubrey September 11, 2026September 11, 2026
Biotechnology

BridgeBio’s PROPEL 3 Update Broadens the Infigratinib Story Beyond Height. The New Results Remain Exploratory.

BridgeBio has reported new exploratory analyses from PROPEL 3, its Phase 3 study of oral…

Jane Aubrey September 10, 2026September 10, 2026
Biotechnology

Leyden Labs’ RIG-101 Clears an Early Safety and Biomarker Hurdle. Phase 2 Must Now Show Clinical Protection.

Leyden Laboratories has reported positive Phase 1 findings for RIG-101, an investigational intranasal innate-immune modulator…

Jane Aubrey September 9, 2026September 9, 2026

Editor Choice

View All
Biotechnology

FDA Expands Sevabertinib’s Accelerated Approval in HER2-Mutant NSCLC. The Response Data Are Encouraging, but Confirmation Still Matters

Jane Aubrey September 11, 2026September 11, 2026
Biotechnology

BridgeBio’s PROPEL 3 Update Broadens the Infigratinib Story Beyond Height. The New Results Remain Exploratory.

Jane Aubrey September 10, 2026September 10, 2026
The Immune Reset: CAR T-Cell Therapy Offers a Potential Cure for Severe Lupus
Biotechnology

The Immune Reset: CAR T-Cell Therapy Offers a Potential Cure for Severe Lupus

Marcus ChenJune 16, 2026June 16, 2026

A pioneering NHS trial successfully utilizes genetically modified T-cells to drive severe, treatment-resistant lupus into remission, signaling a paradigm shift…

The Liquid Biopsy Reality Check: Navigating the Promise and Limits of Blood-Based Cancer Detection
Testing

The Liquid Biopsy Reality Check: Navigating the Promise and Limits of Blood-Based Cancer Detection

Jane AubreyJune 16, 2026June 16, 2026

As multi-cancer early detection tests generate immense excitement, oncologists emphasize the need for rigorous clinical validation and temper expectations regarding…

Beyond the Short Read: How Long-Read Sequencing is Solving the Unsolvable
Genetics

Beyond the Short Read: How Long-Read Sequencing is Solving the Unsolvable

Jane AubreyJune 16, 2026June 16, 2026

A landmark study demonstrates that long-read genome sequencing can replace 15 separate diagnostics for rare genetic diseases, while also illuminating…

The Fiber Buffer: Rethinking Diet and Metabolic Health Through the Microbiome
Nutrition

The Fiber Buffer: Rethinking Diet and Metabolic Health Through the Microbiome

Marcus ChenJune 16, 2026June 16, 2026

New research highlights how specific dietary fibers and prebiotics can stabilize glucose, combat fatty liver, and outperform extreme dietary restrictions.…

Reversing the Clock: The First Human Trial of Cellular Reprogramming
Biohacking

Reversing the Clock: The First Human Trial of Cellular Reprogramming

Amara DialloJune 16, 2026June 16, 2026

The Fiber Buffer: Rethinking Diet and Metabolic Health Through the Microbiome New research highlights how specific dietary fibers and prebiotics…

A Milestone in Gene Therapy: Restoring Sound and the Base Editing Debate
Genetics

A Milestone in Gene Therapy: Restoring Sound and the Base Editing Debate

Jane AubreyJune 16, 2026

The FDA’s landmark approval of an in vivo gene therapy for hearing loss signals a new era for biotechnology, even…

Pharma’s $106 Billion Summer: The Bolt-On Strategy to Beat the Patent Cliff
Pharma

Pharma’s $106 Billion Summer: The Bolt-On Strategy to Beat the Patent Cliff

Marcus ChenJune 16, 2026June 16, 2026

How a surge in targeted mid-sized acquisitions is reshaping oncology and metabolic pipelines as major drugmakers brace for a revenue…

The GLP-1 Supercycle: How the Next Generation of Blockbusters is Reshaping Medicine
Lifestyle

The GLP-1 Supercycle: How the Next Generation of Blockbusters is Reshaping Medicine

Amara DialloJune 16, 2026June 16, 2026

From cardiovascular protection to cognitive decline, the race to dominate a projected $300 billion market moves far beyond weight loss…

The Unraveling of the Managed Care Model: How UnitedHealth’s Crisis is Reshaping the Insurance Landscape
Healthcare

The Unraveling of the Managed Care Model: How UnitedHealth’s Crisis is Reshaping the Insurance Landscape

Jane AubreyJune 16, 2026June 16, 2026

As federal investigations, state lawsuits, and bipartisan pushback against AI-driven prior authorization converge, the health insurance industry faces a profound…

Posts pagination

Previous 1 … 7 8
The Biotech Codex
  • About Us
  • Contact
  • Editorial Policy
  • Submissions

Copyright © 2026 The Biotech Codex